Clinical Trial Update: A Multi-Center Study on the Use of Rho-Kinase Inhibitor to Reduce or Prevent PVR in RRD Eyes at High Risk for PVR [Phase 2, Phase 3]

View source ↗

Summary

A multi-center Phase 2/Phase 3 clinical trial evaluating a Rho-kinase inhibitor to reduce or prevent proliferative vitreoretinopathy in eyes at high risk after …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Proliferative Vitreoretinopathy
• Rhegmatogenous Retinal Detachment

Drugs mentioned

• Rho-kinase inhibitor

Snippet

Sponsor: Wills Eye | Conditions: Rhegmatogenous Retinal Detachment, Proliferative Vitreoretinopathy | Phase 2, Phase 3 | Status: ACTIVE_NOT_RECRUITING